Menu Search
Equities

Inari Medical Inc

IM7:BER

Inari Medical Inc

Actions
  • Price (EUR)43.00
  • Today's Change1.00 / 2.38%
  • Shares traded15.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 15 2024 19:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Inari Medical, Inc. is a medical device company. The Company’s products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. It also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.

  • Revenue in USD (TTM)520.66m
  • Net income in USD-23.62m
  • Incorporated2011
  • Employees1.30k
  • Location
    Inari Medical Inc6001 Oak Canyon, Suite 100IRVINE 92618United StatesUSA
  • Phone+1 (949) 923-4747
  • Fax+1 (302) 655-5049
  • Websitehttps://www.inarimedical.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		NARI:NSQ since
announced		Transaction
value
Limflow SADeal completed01 Nov 202301 Nov 2023Deal completed-22.38%415.00m
Data delayed at least 15 minutes, as of May 15 2024 20:54 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.